EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell–depleting agents

Cary M Looney, Nicolas Strauli, Matthew D Cascino, Hailey Garma, Aaron V Schroeder, Chikara Takahashi, William O'Gorman, Cherie Green, Ann E Herman

Clinical Immunology · 2023-03 · 248 · 109265

DOI: 10.1016/j.clim.2023.109265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2023-03. Verfasst von Cary M Looney und 8 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Hauptthemen laut MEDLINE: B-Lymphocytes, Autoimmune Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F Hoffmann-La Roche Ltd, F. Hoffmann-La Roche, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted B-cell depletion is a useful therapy for many diseases, including autoimmune disorders and certain cancers. We developed a sensitive blood B-cell depletion assay, MRB 1.1, compared its performance with the T-cell/B-cell/NK-cell (TBNK) assay, and assessed B-cell depletion with different therapies. The empirically defined lower limit of quantification (LLOQ) for CD19+ cells in the TBNK assay was 10 cells/μL, and 0.441 cells/μL for the MRB 1.1 assay. The TBNK LLOQ was used to compare differences between B-cell depletion in similar lupus nephritis patient populations who received rituximab (LUNAR), ocrelizumab (BELONG), or obinutuzumab (NOBILITY). After 4 weeks, 10% of patients treated with rituximab retained detectable B cells vs 1.8% with ocrelizumab and 1.7% for obinutuzumab; at 24 weeks 93% of patients who received obinutuzumab remained below LLOQ vs 63% for rituximab. More-sensitive measurements of B cells may reveal differences in potency among anti-CD20 agents, which may associate with clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesAutoimmune DiseasesHumansRituximabKiller Cells, Natural

Stichwörter der Autor:innen

B cellsB-cell depletionCD19CD20Flow cytometryHigh-sensitivity flow cytometry

Substanzen

Rituximab

Autor:innen und Institutionen

  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Genentech, Inc., South San Francisco, CA, USA.
  • Genentech, Inc., South San Francisco, CA, USA. Electronic address: herman.ann@gene.com.

Förderung

  • F Hoffmann-La Roche Ltd
  • F. Hoffmann-La Roche
  • Genentech

Zitieren

APA

Looney, C. M., Strauli, N., Cascino, M. D., Garma, H., Schroeder, A. V., Takahashi, C., O'Gorman, W., Green, C., & Herman, A. E. (2023). Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell–depleting agents. Clinical Immunology, 248, 109265. https://doi.org/10.1016/j.clim.2023.109265

Vancouver

Looney CM, Strauli N, Cascino MD, Garma H, Schroeder AV, Takahashi C, et al. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell–depleting agents. Clinical Immunology. 2023;248:109265. doi:10.1016/j.clim.2023.109265

BibTeX
@article{Looney2023,
  author = {Looney, Cary M and Strauli, Nicolas and Cascino, Matthew D and Garma, Hailey and Schroeder, Aaron V and Takahashi, Chikara and O'Gorman, William and Green, Cherie and Herman, Ann E},
  title = {Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell–depleting agents},
  journal = {Clinical Immunology},
  year = {2023},
  volume = {248},
  pages = {109265},
  doi = {10.1016/j.clim.2023.109265}
}
Kostenlos starten →